Changes in levels of catalase and glutathione in erythrocytes of patients with stable asthma, treated with beclomethasone dipropionate

H.J. Pennings*, P.J.A. Born‡, C.T.A. Evelo‡, E.F.M. Wouters*


ABSTRACT: In asthmatic patients, antioxidant defence is decreased. Although inhaled corticosteroids decrease asthmatic inflammation and modulate reactive oxygen species (ROS) generation, little is known of their effect on cellular antioxidant levels. The aim of this study was to evaluate the effect of inhaled beclomethasone dipropionate (BDP; 1,000 µg/day) on erythrocyte antioxidant levels in stable asthmatic patients.

Forty patients with stable, mild asthma were treated in a double-blind, placebo-controlled, parallel-group study with BDP 250 µg, two puffs b.i.d., for 6 weeks. At entry and every 2 weeks during treatment, erythrocyte antioxidant levels, haematological parameters, pulmonary function tests and asthma symptoms were determined.

The results show that during treatment with BDP, erythrocyte catalase levels increased (at entry (mean±SEM) 41±4, after 6 weeks 54±4 µmol H2O2·min−1·g haemoglobin (Hb)−1, p=0.05 in comparison with placebo). Erythrocyte total glutathione levels significantly decreased after 6 weeks treatment with BDP (from 7.0±0.4 to 6.6±0.3 µmol·g Hb−1 (p=0.04)). In the BDP-treated patients, blood eosinophil counts were higher in patients who responded with an increase in erythrocyte catalase levels during BDP treatment, as compared to those not responding (mean±SEM 340±39 and 153±52 × 106 cells·L−1, respectively, p=0.05).

The present study shows that treatment with inhaled beclomethasone dipropionate results in changes in antioxidant levels in erythrocytes of patients with stable, mild asthma.


Asthma is characterized by reversible airflow obstruction and the presence of a chronic inflammation within the airways. Cells involved in the inflammatory process in asthma have been shown to generate increased amounts of reactive oxygen species (ROS) [1–3] and levels of ROS generation correlate with asthma severity [4]. ROS-genera-
tion is enhanced in bronchoalveolar lavage (BAL) cells of stable asthmatics [5] and increases after antigen challenge [6]. ROS can influence airway cell function by interacting with deoxyribonucleic acid (DNA), altering protein structures, interfering with signal transduction mechanisms by oxidative modification (e.g. β2-adrenergic receptors), contracting airway smooth muscle, increasing vascular permeability and increasing release of secondary inflammatory mediators (i.e. leukotrienes, platelet-activating factor) [7]. Within the lung, powerful antioxidant enzymes are present, both intra- and extracellularly, and the levels of these enzymes may increase following chronic exposure to increased levels of ROS [8, 9]. Levels of glutathione have been shown to be elevated in BAL fluid of patients with stable asthma [10]. In asthma, ROS generation is not only increased within the pulmonary compartment, but also in peripheral blood cells [1, 3]. This observation is in line with data showing the presence of activated leukocytes in the general circulation after allergen challenge [11]. In asthma, evidence for a disturbed oxidant–antioxidant balance has been found in the general circulation. Decreased glutathione peroxidase levels have been reported in serum, platelets and red blood cells (RBC) [12, 13] and levels of selenium, a cofactor for glutathione peroxidase, are reduced in asthmatic patients [13]. Decreased levels of catalase in RBC of asthmatic children have also been reported [14]. Recently, it was shown that the antioxidant capacity is decreased in plasma of asthmatic patients, both in stable and in acute asthma [15].

RBC can be regarded as circulating anti-oxidant carriers, reflecting exposition to ROS [9, 16]. The importance of RBC antioxidant enzymes in protecting target cells from ROS has been shown both in in vitro [17] and in vivo [18] studies. RBC antioxidant enzymes can be determined with a high degree of reproducibility and studies have shown that wide interindividual variations exist [19]. Since RBC are more easily accessible than lung tissue, RBC antioxidant levels have been used in studies evaluating chronic ROS exposure [16, 20, 21].
Corticosteroids play a dominant role in the treatment of asthma owing to their powerful anti-inflammatory effects [22]. So far, few studies have evaluated the effects of inhaled corticosteroids on antioxidant levels in asthma [23]. The aim of this study was to evaluate the influence of inhaled beclomethasone dipropionate (BDP) on antioxidant levels of RBC in patients with mild, stable asthma. The changes were chosen to be studied in RBC, since they represent a long-term index of antioxidant status [16].

Materials and methods

Study design

The present study was performed simultaneously with investigations into the effect of BDP on isocapnic hyperventilation with cold air, the results of which have been reported previously [24]. Forty patients with mild, stable asthma, equally distributed over both sexes, were included in the study. The study design consisted of a double-blind, placebo-controlled, parallel-group study, in which patients were randomly allocated to receive either BDP 250 µg-puff\(^{-1}\), two puffs b.i.d. by metered-dose inhaler or placebo (containing the propellant dichloro-difluoromethane and trichloro-fluoromethane) for 6 weeks. The time schedule consisted of a run-in period of 1 week, followed by a treatment period of 6 weeks, during which control visits were scheduled every 2 weeks. All patients entering the study had a documented bronchial hyperresponsiveness (defined as a provocative dose of histamine causing a 20% fall in forced expiratory volume in one second (PD\(^{20}\)) value <8 µmol) and were all atopic, with a mean number of positive skin tests for aeroallergens of 4.4±2.4 (mean±SD).

Patients were all in a clinically stable condition and showed no evidence of recent respiratory tract infection. None of the patients had been treated with inhaled or oral corticosteroids within the 3 months prior to the study. Only \(\beta_{2}\)-sympathomimetic drugs were allowed for control of asthma.

During the study, patients recorded in a diary, asthma symptoms (0=no complaints, 5=major interference with daily activities), the number of \(\beta_{2}\)-sympathomimetic drugs used for control of asthma and peak expiratory flow rates (PEFR), using mini-Wright peak-flow meters (Aimed; Clement Clarke International Ltd., London, UK). Patients reported the best of three successive measurements of PEFR in the morning and the evening. At every visit, the patient diary was reviewed and pulmonary function was evaluated by flow-volume measurements using a pneumotachograph (Masterlab, Jaeger, Würzburg, Germany).

The activity of these enzymes was determined as described previously [20]. Haemoglobin was determined according to the method of VAN KAMPEN and ZUIJLSTRA [25]. In brief, for glutathione peroxidase, 1 mL of haemolysate was mixed with an equal volume of potassium ferricyanide and KCN containing buffer. Fifty microlitres of the mixture was added to the incubation buffer containing 1 mM GSH, 200 \(\mu\)M NADPH and 1 IU·mL\(^{-1}\) GSSG-reductase and the rate of oxidation of NADPH was measured for 3 min by spectrophotometry at 340 nM. The substrate used was 0.33 mM H\(_2\)O\(_2\) for measurement of selenium dependent glutathione peroxidase. Units of enzyme activity were expressed as \(\mu\)mol NADPH·mg Hb\(^{-1}\) using a molar extinction coefficient for NADPH of 6.22 × 10\(^{3}\)·mM\(^{-1}\)·cm\(^{-1}\).

Superoxide dismutase activity was measured by the method of McCORD and FREDRIICH [26]. A standard curve was prepared using commercially available SOD. The enzyme activity at 25°C was expressed in units of enzyme per mg Hb.

Catalase activity was measured according to AEBI [27], as described previously. Prior to the catalase measurement, lysates were diluted to a concentration of 50 mg Hb·mL\(^{-1}\). At 25°C, 4 µL lysate and 1 mL H\(_2\)O\(_2\) (30 mM) were added to 2 mL PBS. The rapid decomposition of H\(_2\)O\(_2\) was followed during 15 s from the decrease in absorbance at 240 nm. Enzyme activity was expressed as mmol H\(_2\)O\(_2\)-min\(^{-1}\)·g Hb\(^{-1}\) using a molar extinction coefficient for H\(_2\)O\(_2\) of 0.0394 mM\(^{-1}\)·cm\(^{-1}\).

Total glutathione (reduced plus oxidized) and glutathione disulfide levels were determined as described previously [21]. In brief, for determination of total glutathione,
RBC were treated with an equal volume of 10% (w/v) trichloroacetic acid. Supernatants were diluted 9-fold with 100 mM sodium/potassium buffer (pH 7.4) and measured using the cyclic oxidation-reduction method essentially as described by Andersen [28]. For determination of glutathione S-transferase (EC 2.5.1.18) activity with CDNB as a substrate, full lysis of the thawed cells was induced with 5 volumes of ice-cold water (10–15 min), using the method of Habig and Jacoby [29] with previously described modifications [30].

Statistics

All data described are mean ± SEM, unless otherwise specified. Effect of treatment was expressed as changes from baseline. Since antioxidant enzyme levels were not distributed normally, nonparametric tests were used for analysis between treatment groups (Mann-Whitney U-test). A p-value < 0.05 was considered statistically significant (two-sided test). Correlations between parameters were evaluated using the Spearman’s rank correlation coefficient. The statistical package SPSS/PC+ (version 6.1-Windows; SPSS Inc., Chicago, IL, USA) was used for all calculations.

Results

Forty patients were included in the study. Demographic variables are given in Table 1. As reported previously, patients in the BDP group demonstrated a significantly higher FEV1 than the placebo group (101 versus 92% predicted, p = 0.02). Eighteen patients in the BDP group and 17 patients in the placebo group completed the study. In the placebo group, the main reason for dropping-out was withdrawal of consent (three patients), whereas in the BDP group exacerbation of eczema, necessitating oral corticosteroid treatment (one patient) and noncompliance (one patient) were the reasons for exclusion from the study.

Table 1. – Subjects characteristics: anthropometric and spirometric data

<table>
<thead>
<tr>
<th>BDP group</th>
<th>Placebo group</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex M/F</td>
<td>10/10</td>
</tr>
<tr>
<td>Smokers yes/no</td>
<td>4/16</td>
</tr>
<tr>
<td>Age yrs</td>
<td>79±7</td>
</tr>
<tr>
<td>Height cm</td>
<td>172±7</td>
</tr>
<tr>
<td>Weight kg</td>
<td>75±12</td>
</tr>
<tr>
<td>FEV1 % pred</td>
<td>101±12</td>
</tr>
<tr>
<td>PD20 µmol</td>
<td>1.3±1.3</td>
</tr>
<tr>
<td>Haemoglobin mmol L⁻¹</td>
<td>8.7±0.6</td>
</tr>
<tr>
<td>Leukocytes ×10⁹ cells L⁻¹</td>
<td>6.3±2.0</td>
</tr>
<tr>
<td>Eosinophils ×10⁶ cells L⁻¹</td>
<td>318±148</td>
</tr>
<tr>
<td>IgE kU L⁻¹</td>
<td>430±519</td>
</tr>
</tbody>
</table>

At baseline, no differences in RBC antioxidant enzymes were observed between the groups (table 2). In the BDP group, catalase levels could not be determined for two patients due to technical reasons. Smoking patients were equally distributed between groups (table 1); no differences in antioxidant levels were observed between smokers and nonsmokers (data not shown). Furthermore, no differences were observed in Hb, white blood cell count and total number of eosinophils between the groups (table 1). At entry, for the whole group a significant positive correlation was observed between levels of glutathione peroxidase and glutathione S-transferase (r = 0.51, p = 0.001) and an inverse correlation for glutathione peroxidase and SOD (r = -0.54, p < 0.001). No significant correlations were observed between levels of antioxidant enzymes and baseline pulmonary function, levels of bronchial hyperresponsiveness, immunoglobulin (IgE) or white blood cell parameters.

During treatment with BDP, a gradual increase in RBC catalase activity was observed, which reached statistical significance after 6 weeks (at entry (mean ± SEM) 54±4 µmol H₂O₂·min⁻¹·g Hb⁻¹, after 6 weeks 58±4 µmol H₂O₂·min⁻¹·g Hb⁻¹, p = 0.05) (figs. 1a and 2a). Interestingly, for total RBC glutathione an opposite change was observed; during BDP treatment, a gradual decrease in total glutathione levels was observed, which also reached statistical significance after 6 weeks of treatment (at entry (mean ± SEM) 7.0±0.4 µmol·g Hb⁻¹, at weeks 6.6±0.3 µmol·g Hb⁻¹, p = 0.04) (figs. 1b and 2b). No correlation was present between changes in catalase and total glutathione in RBC. However, the increase of RBC catalase activity during treatment with BDP showed a weak inverse correlation with the initial level of RBC catalase activity (r = -0.51, p = 0.04). For changes in total glutathione, a similar trend was detected, although not statistically significant (r = -0.42, p = 0.08). Changes in the levels of catalase or glutathione were not correlated with pulmonary function, level of bronchial hyperresponsiveness or IgE. However, when the BDP group was divided into responders (increase in catalase at 6 weeks) and nonresponders (stable or decreased catalase), a significant difference was observed between the two groups in the number of eosinophils at entry (number of eosinophils at entry in nonresponders (mean ± SEM) 153±2 × 10⁶ cells L⁻¹ versus responders 340±39 × 10⁶ cells L⁻¹, p = 0.05; fig. 3). No differences in pulmonary function, airway hyperresponsiveness or baseline antioxidant levels were present between responders and nonresponders. For glutathione, no differences in the

Table 2. – Baseline red blood cell antioxidant levels in asthmatic patients

<table>
<thead>
<tr>
<th></th>
<th>BDP</th>
<th>Placebo</th>
</tr>
</thead>
<tbody>
<tr>
<td>SOD U·mg Hb⁻¹</td>
<td>1.1±0.09</td>
<td>1.2±0.10</td>
</tr>
<tr>
<td>GP U·mg Hb⁻¹</td>
<td>3.2±0.38</td>
<td>2.9±0.28</td>
</tr>
<tr>
<td>GST U·g Hb⁻¹</td>
<td>1.9±0.14</td>
<td>1.8±0.15</td>
</tr>
<tr>
<td>Catalase µmol H₂O₂·min⁻¹·g Hb⁻¹</td>
<td>41.1±3.7</td>
<td>47.1±3.3</td>
</tr>
<tr>
<td>Total glutathione µmol·g Hb⁻¹</td>
<td>7.0±0.35</td>
<td>6.2±0.25</td>
</tr>
</tbody>
</table>

Data are presented as mean ± SEM. BDP: beclomethasone dipropionate; SOD: superoxide dismutase; Hb: haemoglobin; GP: glutathione peroxidase; GST: glutathione-S-transferase. At baseline, no significant differences were observed between the two groups of asthmatic patients.
number of eosinophils could be observed between responders and nonresponders.

Activities of SOD, glutathione peroxidase and glutathione S-transferase did not change during treatment with BDP (data not shown). Also, during treatment with BDP, no significant changes were observed in asthma symptom scores, use of \( \beta_2 \)-rescue medication and pulmonary function, as reported previously [24].

During treatment with BDP, a significant decrease was observed in the total number of eosinophils in peripheral blood; this decrease was already observed after 2 weeks of treatment (at entry \( \text{mean}\pm\text{SEM} \ 318\pm33 \times 10^6 \text{ cells.L}^{-1} \), after 2 weeks BDP \( 228\pm31 \times 10^6 \text{ cells.L}^{-1} \); \( p<0.02 \) between groups) and number of eosinophils remained well below baseline levels during the rest of the study period (fig. 4).

**Discussion**

The present study demonstrates that erythrocyte levels of catalase increase and total glutathione levels decrease in patients with mild stable asthma, treated with BDP. Additionally, treatment with BDP resulted in a significant decrease in the total number of circulating eosinophils.

In asthma, numerous studies have shown that ROS are involved in the inflammatory process [1–7]. Alveolar macrophages of asthmatic patients demonstrated enhanced chemiluminescence, which correlated with asthma severity and bronchial hyperresponsiveness [4, 5]. An increased oxidative burden has been noted, not only in the pulmonary compartment, but also in peripheral blood cells which generate higher levels of ROS both spontaneously and after stimulation in comparison to healthy controls. This has been observed for both blood polymorphonuclear neutrophils and monocytes [1, 2], and also for blood eosinophils [3].

Antioxidant levels increase in response to oxidant stress and can ameliorate oxidant induced injury [9]; knowledge of antioxidant defence levels is therefore essential to predict total outcome of tissue damage. In asthma, it has been shown that antioxidant levels are decreased, both in the pulmonary compartment [23, 31] as well as in peripheral blood [1, 12]. BDP have been used to monitor long-term alterations in antioxidant status in chronic pulmonary disorders [16, 20], as well as in asthma [14].

In the present study, treatment with BDP resulted in an increase in RBC catalase activity, whereas no changes
were observed in levels of glutathione peroxidase, SOD and glutathione S-transferase. RBC express high levels of catalase in contrast to, for instance, bronchial epithelial cells [9]. Catalase is one of the most important mechanisms by which RBC dispose of H$_2$O$_2$ [17] and RBC catalase has been demonstrated to protect cells from ROS burden [17]. Therefore, the increase in RBC catalase in the present study reflects an increased defence against ROS exposure. The observed negative correlation of baseline catalase levels with the response of catalase to BDP treatment, observed in the present study, leads to the assumption that RBC catalase levels may be a marker of the asthmatic inflammation, where lower levels of catalase reflect enhanced exposure to ROS. Indeed in asthmatic children, catalase levels have been shown to be decreased in comparison to controls [14].

Several mechanisms may be involved in the effect of BDP on RBC catalase. Treatment with BDP attenuates the local inflammatory response as is shown in bronchial biopsies [32] and BAL [33]. This may lead to a reduction in the local formation of ROS. Recently, it was shown that monocytes of asthmatic patients, treated with inhaled steroids, produced less superoxide anions when stimulated with phorbol myristate-acetate (PMA) in comparison with monocytes of untreated asthmatic patients [34]. Furthermore, inhaled corticosteroids may decrease levels of inflammatory mediators, like transforming growth factor (TGF)-β, which normally inhibit antioxidant gene activity [31], resulting in increased gene transcription. Animal studies have shown that corticosteroids influence catalase gene-transcription. Dexamethasone has been shown in vitro to increase catalase messenger ribonucleic acid (mRNA) in perinatal rat lung cells [35] and to enhance SOD and glutathione peroxidase enzyme activity in the foetal rat lung [36]. Administration of corticosteroids in vivo increased catalase and glutathione peroxidase activity in rat peritoneal macrophages and significantly inhibited in vitro hydrogen peroxide production in peritoneal macrophages [37]. Effects of corticosteroids on human cells are less clear. Although inhaled corticosteroids failed to influence ROS generation in stimulated alveolar macrophages [33], corticosteroids significantly reduced superoxide production in stimulated polymorphonuclear cells [38] and monocytes [34].

The present study also observed a reduction in RBC total glutathione during treatment with BDP. Few data exist regarding glutathione levels in RBC of asthmatic patients [14]. Both animal and human studies have shown that glutathione levels can increase during oxidant stress. Increased levels of glutathione were demonstrated in BAL of asthmatic patients [10], in RBC of patients with chronic occupational lung disorders [8] and in RBC of volunteers, participating in exercise training [21]. The decrease in RBC glutathione, observed in the present study, may therefore reflect decreased oxygen radical exposure. Indeed, animal studies have observed that corticosteroids decrease oxidative metabolism, followed by a decrease in antioxidant enzyme levels [39]. Another explanation for the observed decrease of total glutathione in the present study may be that GSSG is transported out of the RBC; however, this mechanism mainly occurs in heart and liver cells [9] and is only observed in RBC when exposed to very high levels of ROS. In addition, the observation of a decrease in RBC glutathione indirectly argues against systemic effects of inhaled BDP, since systemically applied corticosteroids have been shown in mice to increase hepatic synthesis of glutathione [40].

The present study demonstrated that patients responding to BDP with an increase in catalase, had higher eosinophil counts at entry than the patients not responding. In addition, the present study supports data from a previous study which also demonstrated a reduction in peripheral blood eosinophils during treatment with inhaled corticosteroids [41]. Since the number of blood eosinophils have been shown to correlate with asthma-severity [42], the present study suggests that patients with higher levels of inflammation show lower levels of RBC catalase and higher blood eosinophil counts. The fact that the present study did not observe changes in asthma-severity may be explained by the relative insensitivity of these parameters to monitor subtle inflammatory changes in patients with mild, stable asthma.
In conclusion, the present study demonstrates that in patients with mild, stable asthma, treatment with inhaled beclomethasone dipropionate results in an increase in red blood cell catalase levels and, at the same time, a decrease in red blood cell glutathione. Peripheral blood eosinophil counts were higher in patients who demonstrated an increase in red blood cell catalase during treatment with beclomethasone dipropionate. It is speculated that inhaled beclomethasone dipropionate decreases reactive oxygen species generation within the lung, which leads to a subsequent change in systemic antioxidant levels. Further studies, simultaneously evaluating reactive oxygen species formation within the lung while monitoring antioxidant defences, will be needed in order to improve the understanding of the effects of inhaled corticosteroids on antioxidant defences in asthma.

Acknowledgements. The authors wish to thank E. Rhijsburger and A. Knaapen (Department of Health Risk Analysis and Toxicology) and L. Baas (Department of Pharmacology) for their assistance with the analyses.

References


